Valone Collins, NP
Family · Belpre, OHNPI 1134765878
Payments from drug & device makers
Across 257 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$975
- Lilly USA, LLC$827
- Corcept Therapeutics$472
- Boehringer Ingelheim$436
- Sanofi-aventis U.S. LLC$309
- Bayer$291
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,30398%
- Education$1042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $975 |
| Lilly USA, LLC | 45 | $827 |
| Corcept Therapeutics | 17 | $472 |
| Boehringer Ingelheim | 19 | $436 |
| Sanofi-aventis U.S. LLC | 13 | $309 |
| Bayer | 9 | $291 |
| Abbott | 8 | $279 |
| AstraZeneca(2 entities) | 13 | $276 |
| Insulet Corporation | 12 | $251 |
| Xeris Pharmaceuticals, Inc. | 9 | $162 |
| Dexcom, Inc. | 7 | $152 |
| Averitas Pharma Inc. | 6 | $125 |
| Amgen | 8 | $118 |
| BETA Bionics, Inc. | 2 | $111 |
| OPKO Pharmaceuticals, LLC | 4 | $76 |
| Medtronic | 3 | $62 |
| Cequr Corporation | 2 | $61 |
| Tandem Diabetes Care, Inc. | 3 | $58 |
| Novartis | 3 | $51 |
| Mannkind Corporation | 2 | $36 |
| AbbVie | 2 | $30 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Radius Health, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| BD | 1 | $20 |
| Chiesi USA, Inc. | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| RGH Enterprises LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,406 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 306 | $501,888 |
| JardianceEmpagliflozin | 415 | $445,176 |
| TrulicityDulaglutide | 204 | $250,717 |
| MounjaroTirzepatide | 173 | $234,025 |
| FarxigaDapagliflozin Propanediol | 132 | $150,736 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 84 | $50,338 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $44,554 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 34 | $43,436 |
| JanuviaSitagliptin Phosphate | 48 | $40,828 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 190 | $25,641 |
| RybelsusSemaglutide | 18 | $23,520 |
| TradjentaLinagliptin | 18 | $20,674 |
| Novolog FlexpenInsulin Aspart | 59 | $20,613 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $20,286 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $19,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $975 | $525,408324 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $827 | $484,742377 claims |
| Boehringer IngelheimJardiance, Tradjenta | $436 | $465,850433 claims |
| AstraZenecaFarxiga | $276 | $150,736132 claims |
| AbbVieSynthroid | $30 | $4,83685 claims |
| IBSA Pharma Inc.Tirosint-Sol | $15 | $1,94112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Belpre
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.